Please login to the form below

Hanmi

This page shows the latest Hanmi news and features for those working in and with pharma, biotech and healthcare.

Merck entered into a licensing agreement with Hanmi Pharmaceutical in 2020 for the licensing rights to efinopegdutide.

Merck enters agreement with Hanmi for investigational NASH drug

In 2015, J&J and Hanmi entered an alliance to develop efinopegdutide to treat diabetes and obesity, with Hanmi receiving an upfront payment of $105m for the drug. ... The deal with Hanmi builds on Merck’s existing NASH pipeline, which includes a
Lilly drops Hanmi-partnered arthritis drug

Lilly licensed HM71224 (LY3337641) from South Korean biotech Hanmi Pharmaceutical in 2015 for $50m upfront and milestones of $640m, but after two years of phase II testing has concluded that there ... Hanmi reported the decision to the Korean financial
Sanofi's diabetes head Pascale Witz to leave the company

She was instrumental in signing important strategic collaborations, including those with Verily Life Sciences (a subsidiary of Google) and Hanmi Pharmaceuticals.”.
Boehringer pledges €11bn to fund R&D drive

In July, Boehringer signed an agreement with South Korea's Hanmi Pharmaceuticals to develop a third-generation epidermal growth factor receptor (EGFR) targeting drug for lung cancer, a potential follow-up
J&J and Hanmi collaborate on diabetes and obesity

Alliance worth up to$915m. Johnson and Johnson have entered into an alliance with Hanmi Pharmaceuticals to develop new treatments for diabetes and obesity. ... Additionally if HM12525A is successfully commercialised, Hanmi would receive double-digit

More from news
Approximately 4 fully matching, plus 7 partially matching documents found.

Deal Watch October 2016

Hanmi (SK) / Jul 15. Boehringer Ing. (DE). Olmuntinib / Lung cancer.
Deal Watch September 2016

No financial terms were disclosed. Genentech signed an exclusive licence [global excluding South Korea] with Hanmi Pharmaceutical to develop and market HM95573, a pan-RAF inhibitor. ... 1, 000+. Hanmi / Genentech. Licence. HM95573, a selective
Deal Watch November 2015

$900m of which two were with the same company, Hanmi Pharmaceutical, a Korean public company. ... Option to co-develop/co-commercialise EU/US. 1, 560. Hanmi Pharmaceutical. Janssen Pharmaceuticals. Licence.
Medius Deal Watch table for March 2015

750. Hanmi / Eli Lilly. Licence and collaboration. Phase 1 BTK inhibitor for treatment of lupus.
Pharma deals in March 2015

Lilly's expedition to the Far East also generated another deal this month, the licence of a phase 1 BTK inhibitor from the Korean company Hanmi for up to $690m.